Clinical isoflurane metabolism by cytochrome P450 2E1

Anesthesiology

Volumn 90, Issue 3, 1999, Pages 766-771

  Kharasch, Evan D ^a   Hankins, Douglas C ^a   Cox, Kathy ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP2E1; Drug interactions; Enflurane; Halothane; Isoniazid; Sevoflurane; Toxicity

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2E1; DISULFIRAM; FENTANYL; FLUORIDE; ISOFLURANE; PROPOFOL; SUXAMETHONIUM; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; INHALATION ANESTHESIA; INHALATIONAL DRUG ADMINISTRATION; MALE; OPERATION DURATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0032965115     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199903000-00019     Document Type: Article

References (38)

1. Bradshaw JJ, Ivanetich KM: Isoflurane: A comparison of its metabolism by human and rat hepatic cytochrome P-450. Anesth Analg 1984; 63:805-13
2. Christ DD, Satoh H, Kenna JG, Pohl LR: Potential metabolic basis for enflnrane hepatitis and tlie apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16:135-40
3. Stocking RK, Blitt CD, Cohen PJ, Merin RG: Hepatic dysfunction after isoflurane anesthesia. Anesth Analg 1987; 66:147-53
4. Gunza JT, Pashayan AG: Postoperative elevation of serum transaminases following isoflurane anesthesia. J Clin Anesth 1992; 4:336-41
5. Sinha A, Clatch RJ, Stuck G, Blumenthal SA, Patel SA: Isoflurane hepatotoxicity: A case report and review of the literature. Am J Gastroenterol 1996; 91:2406-9
6. Kenna JG, Neuberger J, Williams R: Evidence for expression in human liver of halothane-induced neoantigens by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8:1635-41
7. Ilyin GP, Rissel M, Malledant Y, Tanguy M, Guillouzo A: Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane. Biochem Pharmacol 1994; 48:561-7
8. Ray DC, Drummond GB: Halothane hepatitis. Br J Anaesth 1991; 67:84-99
9. Gut J, Christen U, HuwylerJ: Mechanisms of halothane toxicity: Novel insights. Pharmacol Ther 1993; 58:133-55
10. Davidkova T, Kikuchi H, Fujii K, Mukaida K, Sato N, Kawachi S, Morio M: Biotransformation of isoflurane: Urinary and serum fluoride ion and organic fluorine. ANESTHESIOLOGY 1988; 69:218-22
11. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, Cox K: The role of cytochrome P450 3A4 in alfcntanil clearance: Implications for interindividual variability in disposition and perioperative drug interactions. AXESTIIESIOLOGY 1997; 87:36-50
12. Kharasch ED, Thummel KE, Mautz D, Bosse S: Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 1994; 55:434-40
13. Kharasch ED, Armstrong AS, Gunn K, Artru A, Cox K: Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. ANESTIIESIOLOGY 1995; 82:1379-88
14. Kharasch ED, Hankins D, Mautz D, Thummel KE: Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 1996; 347:1367-71
15. Thummcl KE, Kharasch ED, Podoll T, Kunze K: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993; 21:350-7
16. Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. A.NESTHESIOLOGY 1993; 79:795-807
17. Gauntlett IS, Koblin DD, Fahey MR, Konopka K, Greunke LD, Waskell L, Eger El II: Metabolism of isoflurane in patients receiving isoniazid. Anesth Analg 1989; 69:245-9
18. Kharasch ED, Thummel K, Mhyre J, Lillibridge J: Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53:643-50
19. Guengerich FP, Kirn D-H, Iwasaki M: Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem ResToxicol 1991; 4:168-79
20. Spracklin D, Hankins DC, Fisher JM, Tluimmel KE, Kharasch ED: Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism. J Pharmacol Exp Ther 1997; 281:400-11
21. Hankins DC, Kharasch ED: Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography. J Chromatogr B 1997; 692: 413-8
22. Holaday DA, Fiserova-Iiergerova V, Latto IP, Zumbiel MA: Resistance of isoflurane to biotransformation in man. ANESTHESïOLOGY 1975; 43:325-32
23. Mazze RI, Cousins MJ, Darr GA: Renal effects and metabolism of isoflurane in man. A.NESTHESIOLOGY 1974; 40:536-42
24. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS: I lydrox}lation of chlorzoxazone as a specific probe for human liver cytochrome P-450HE1. Chem Res Toxicol 1990; 3:565-73
25. Yamazaki H, Inui Y, Yun OH, Guengerich FP, Shimada T: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialk} lamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13:1789-94
26. Camus A-M, Geneste O, Honkakoski P, Bereziat J-C, Henderson CJ, Wolf CR, Bartsch II, Lang MA: High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinogen 1993; 7:268-75
27. Duescher RJ, Elfarra AA: Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: Evidence for major roles by cytochromes P450 2A6 and 2E1. Arch Biochem Biophys 1994; 311:342-9
28. Tiano HF, Hosokawa M, Chulada PC, Smith PB, Wang R-L, Gonzalez FJ, Crespi CL, Langenbach R: Retroviral mediated expression of human cytochrome P4502A6 in C3H/10T1/2 cells confers transformabilit}- by 4 methylnitrosamino H3-pyridyl l-butanone (NNK). Carcinogenesis 1993; 14:1421-7
29. ChangTKH, Gonzalez FJ, Waxman DJ: Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311:437-42
30. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-93
31. Kharasch ED, Hankins DC, Baxter PJ, Thummel KE: Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Tlier 1998; 64:39-45
32. Guengerich FP: Human cytochrome P450 enzymes, Cytochrome P450: Structure, Mechanism and Biochemistry. Edited by Ortiz de Montellano PR. New York, Plenum Press, 1995, pp 473535
33. Emery MG, Jubert C, Tliummel KE, Kharasch ED: Using disulfiram, a mechanism based inhibitor, and chlorzoxazone to assess in vivo resynthesis of CYP2E1 in humans. Proceedings of the 12th International Symposium on Microsomes and Drug Oxidations; July 1998; Montpellier, France, p. 288
34. Kharasch ED, Hankins DC, Tliummel KE: Human kidney niethoxyflurane and sevoflurane metabolism: Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. ANESTIIESIOLOGY 1995; 82:689-99
35. Zand R, Nelson SD, SlatteryJT, Tliummel KE, Kalhorn TF, Adams SP, Wright JM: Inhibition and induction of cytochrome P4502El-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54:142-9
36. O'Shea D, Kim RB, Wilkinson GR: Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 1997; 43:99-103
37. Chien JY, Tliummel KE, Slattery JT: Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25:1165-74
38. Van Dyke RA: Enflurane, isoflurane, and methoxyflurane metabolism in rat hepatic microsomes from ethanol-treated animals. AXESTHESIOLOCY 1983; 58:221-4